1. Home
  2. ADAM vs ENGN Comparison

ADAM vs ENGN Comparison

Compare ADAM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADAM

Adamas Trust Inc.

N/A

Current Price

$7.42

Market Cap

665.0M

Sector

Technology

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$6.89

Market Cap

647.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ADAM
ENGN
Founded
2003
1999
Country
United States
Canada
Employees
221
82
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
665.0M
647.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADAM
ENGN
Price
$7.42
$6.89
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$9.17
$21.00
AVG Volume (30 Days)
591.0K
544.3K
Earning Date
04-29-2026
03-09-2026
Dividend Yield
12.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.52
N/A
P/E Ratio
$41.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.45
$2.66
52 Week High
$8.76
$12.25

Technical Indicators

Market Signals
Indicator
ADAM
ENGN
Relative Strength Index (RSI) 34.12 31.71
Support Level $6.85 $6.18
Resistance Level $7.61 $7.63
Average True Range (ATR) 0.23 0.64
MACD -0.08 -0.05
Stochastic Oscillator 9.62 8.01

Price Performance

Historical Comparison
ADAM
ENGN

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: